Compare Merck & Co., Inc. (MRK) vs Toast Inc. Class A Common Stock (TOST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Toast Inc. Class A Common Stock — how do they compare? Merck & Co., Inc. trades at $150.66 (market cap $350.29B), while Toast Inc. Class A Common Stock trades at $29.65 (market cap $17.85B). The key difference: Merck & Co., Inc. is far larger — about 19.6× Toast Inc. Class A Common Stock's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Toast Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Toast Inc. Class A Common Stock for 0 Days on average.
| MRK | TOST | |
|---|---|---|
Market Cap | $350.29B | $17.85B |
Volume | 8,158,912 | 6,311,718 |
Sector | Health | Technology |
52-Week High | $156.43 | $39.02 |
52-Week Low | $82.49 | $22.33 |
Typical Hold Time | 98 Days | 0 Days |
Enterprise Value | $397.05B | $16.10B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $141.98, down 2.39% on the day, with a bullish technical signal from moving averages and a neutral RSI. Revenue grew to $65.01B in 2025, with net income of $18.25B and a profit margin of 28.07%. Recent news highlights the acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors increased holdings. The stock shows strong earnings beats in recent quarters, with Q3 2026 results pending.
The outlook remains positive with a consensus price target of $158.50, implying 11.6% upside, supported by 68% analyst buy ratings. Risks include high P/E of 113.58, debt-to-asset ratio rising to 36.06% in 2025, and competitive pressures in pharmaceuticals. The acquisition strategy may drive growth but carries integration risks.
Toast (TOST) trades at $30.89, down 1.37% on the day, with neutral technical indicators showing support at $30 and resistance at $32. The company demonstrates strong fundamental performance with 23% revenue growth in Q2 2026 to $1.91B and expanding profit margins, though valuation metrics remain elevated with a P/E of 39.1. Recent expansion into convenience stores with Toast Fuel and AI-driven product enhancements signal continued growth initiatives.
The outlook remains positive with 61.8% analyst buy ratings and a $38.22 consensus price target representing 24% upside potential. Key risks include execution challenges in new market segments and competitive pressures in the restaurant technology space, while strong earnings beats and institutional support provide confidence in the growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Toast Inc. Class A Common Stock
Toast Inc. provides a cloud-based technology platform for the restaurant industry, combining point-of-sale hardware and software with payment processing, online ordering, payroll, and supplier management tools. The platform serves restaurants ranging from single locations to multi-unit groups across US.
Read more on TOST →
